TrialStudy of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Trial details
- Registry ID
- NCT03083873
- Phase
- Phase 2
Drug research
LN-145-S1
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as TIL, autologous tumor infiltrating lymphocytes; TIL, autologous tumor-infiltrating lymphocytes, PD-1-selected TIL
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873 | IOVA | Phase 2 | Completed | 2022-08-08Actual |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 | IOVA | Phase 2 | Terminated | 2026-02-20Actual |
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Trial details
- Registry ID
- NCT03645928
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |